CA2803995A1 - Administration d'acides nucleiques fonctionnels dans des cellules de mammiferes via de minicellules intactes derivees par bacteries - Google Patents

Administration d'acides nucleiques fonctionnels dans des cellules de mammiferes via de minicellules intactes derivees par bacteries Download PDF

Info

Publication number
CA2803995A1
CA2803995A1 CA2803995A CA2803995A CA2803995A1 CA 2803995 A1 CA2803995 A1 CA 2803995A1 CA 2803995 A CA2803995 A CA 2803995A CA 2803995 A CA2803995 A CA 2803995A CA 2803995 A1 CA2803995 A1 CA 2803995A1
Authority
CA
Canada
Prior art keywords
minicell
functional nucleic
nucleic acid
minicells
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2803995A
Other languages
English (en)
Other versions
CA2803995C (fr
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EnGeneIC Molecular Delivery Pty Ltd
Original Assignee
EnGeneIC Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EnGeneIC Molecular Delivery Pty Ltd filed Critical EnGeneIC Molecular Delivery Pty Ltd
Priority claimed from CA 2577938 external-priority patent/CA2577938C/fr
Publication of CA2803995A1 publication Critical patent/CA2803995A1/fr
Application granted granted Critical
Publication of CA2803995C publication Critical patent/CA2803995C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2803995A 2004-08-26 2005-08-25 Administration d'acides nucleiques fonctionnels dans des cellules de mammiferes via de minicellules intactes derivees par bacteries Expired - Lifetime CA2803995C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60443304P 2004-08-26 2004-08-26
US60/604,433 2004-08-26
CA 2577938 CA2577938C (fr) 2004-08-26 2005-08-25 Administration d'acides nucleiques fonctionnels dans des cellules de mammiferes via de minicellules intactes derivees par bacteries

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA 2577938 Division CA2577938C (fr) 2004-08-26 2005-08-25 Administration d'acides nucleiques fonctionnels dans des cellules de mammiferes via de minicellules intactes derivees par bacteries

Publications (2)

Publication Number Publication Date
CA2803995A1 true CA2803995A1 (fr) 2006-03-02
CA2803995C CA2803995C (fr) 2014-06-10

Family

ID=47711434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2803995A Expired - Lifetime CA2803995C (fr) 2004-08-26 2005-08-25 Administration d'acides nucleiques fonctionnels dans des cellules de mammiferes via de minicellules intactes derivees par bacteries

Country Status (1)

Country Link
CA (1) CA2803995C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9731011B2 (en) 2013-10-04 2017-08-15 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9731011B2 (en) 2013-10-04 2017-08-15 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
US10500277B2 (en) 2013-10-04 2019-12-10 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

Also Published As

Publication number Publication date
CA2803995C (fr) 2014-06-10

Similar Documents

Publication Publication Date Title
US10426736B2 (en) Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
AU2007278899B2 (en) Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
CA2803995C (fr) Administration d'acides nucleiques fonctionnels dans des cellules de mammiferes via de minicellules intactes derivees par bacteries
AU2017203234B2 (en) Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
HK1163160B (en) Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
WO2009113579A1 (fr) Molécule d'acide nucléique bicaténaire adaptée pour la prévention ou le traitement du cancer, inhibiteur de prolifération de cellules cancéreuses, et préparation pharmaceutique
HK1129845B (en) Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
AU2012261512A1 (en) Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130205

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240812

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240812